Repligen Corporation, founded in 1981 and headquartered in Waltham, Massachusetts, United States, provides advanced bioprocessing technologies to the global biopharmaceutical industry. The company drives revenue by supplying proprietary reagents, chromatography resins, and single‐use systems to major pharmaceutical firms. Under the leadership of CEO Robert E. Dutton, Repligen has secured an estimated 15-20% market share in its niche through innovative process solutions. It is focused on strategic expansion and R&D investments to fuel double-digit growth in the near term.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
738,256
634,439
632,362
801,536
Cost of Sales
352,011
359,794
353,922
345,830
Gross Profit
386,245
274,645
278,440
455,706
Selling, General & Administrative Expenses
290,508
263,368
218,584
215,829
Research & Development Expenses
54,177
43,200
42,722
43,936
Other Operating Expenses
(13,607)
3,191
(30,569)
(28,729)
Operating Profit
55,167
(35,114)
47,703
224,670
Interest and Investment Income
27,574
35,827
24,135
6,978
Interest Expense
(23,173)
(22,574)
(10,578)
(2,977)
Non-Operating Income
10,031
2,905
4,451
(15,061)
Total Non-Operating Income
14,432
16,158
18,008
(11,060)
Income Before Provision for Income Taxes
62,383
(27,035)
56,707
219,140
Provision for Income Taxes
13,489
(1,521)
21,111
33,181
Consolidated Net Income
48,894
(25,514)
35,596
185,959
Net Income Attributable to Common Shareholders
48,894
(25,514)
35,596
185,959
Basic EPS
0.87
-0.46
0.64
3.35
Diluted EPS
0.86
-0.46
0.63
3.24
Basic Weighted Average Shares Outstanding
56,234
55,937
55,720
55,460
Diluted Weighted Average Shares Outstanding
56,561
55,937
56,377
57,455
Shares Outstanding
56,325
56,092
55,766
55,558
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
566,021
757,355
751,323
523,458
Short-Term Investments
201,607
—
—
100,299
Total Cash and Cash Equivalents
767,628
757,355
751,323
623,757
Accounts Receivable
158,587
134,115
124,161
116,247
Total Trade Receivables
158,587
134,115
124,161
116,247
Inventories
170,458
142,964
202,321
238,277
Other Current Assets
40,712
31,607
33,541
19,837
Total Current Assets
1,137,390
1,066,040
1,111,350
998,118
Net Property, Plant & Equipment
306,152
333,116
322,955
315,696
Net Intangible Assets
386,147
397,897
406,957
360,618
Goodwill
1,114,410
1,031,000
987,120
855,513
Other Long-Term Assets
5,607
1,617
2,807
1,655
Total Assets
2,949,700
2,829,670
2,831,190
2,531,600
Accounts Payable
30,010
32,134
19,563
27,554
Accrued Expenses
79,208
62,423
57,313
71,120
Current Portion of Long-Term Debt
—
—
69,452
284,615
Current Portion of Leases
21,559
15,104
5,631
6,957
Other Current Liabilities
5,049
17,126
12,983
13,950
Total Current Liabilities
135,826
126,787
164,942
404,196
Long-Term Debt
542,213
525,567
510,143
—
Leases
126,176
145,576
126,578
131,389
Other Long-Term Liabilities
39,355
59,018
64,677
85,315
Total Long-Term Liabilities
707,744
730,161
701,398
216,704
Total Liabilities
843,570
856,948
866,340
620,900
Common Stock
563
561
558
556
Additional Paid-in Capital
1,651,850
1,617,340
1,569,230
1,547,270
Accumulated Other Comprehensive Income
(2,531)
(52,533)
(37,808)
(34,394)
Retained Earnings
456,248
407,354
432,868
397,272
Total Common Shareholders' Equity
2,106,130
1,972,720
1,964,850
1,910,700
Total Shareholders' Equity
2,106,130
1,972,720
1,964,850
1,910,700
Total Liabilities and Shareholders' Equity
2,949,700
2,829,670
2,831,190
2,531,600
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
48,894
(25,514)
35,596
185,959
Depreciation & Amortization
78,745
69,673
68,556
50,985
Share-Based Compensation Expense
32,605
48,070
25,575
27,316
Other Adjustments
8,053
22,244
4,286
(22,339)
Changes in Trade Receivables
(17,165)
(14,031)
(3,312)
(3,596)
Changes in Inventories
(14,947)
56,895
40,973
(57,204)
Changes in Accounts Payable
(4,150)
12,898
(9,803)
(8,197)
Changes in Accrued Expenses
11,813
6,106
(21,518)
(2,019)
Changes in Other Operating Activities
(26,431)
(947)
(26,435)
1,196
Cash from Operating Activities
117,417
175,394
113,918
172,083
Capital Expenditure
(23,519)
(25,677)
(36,222)
(84,834)
Proceeds from Sale of Property, Plant & Equipment
238
—
—
—
Purchases of Intangible Assets
(2,211)
(7,228)
(2,766)
(45,000)
Purchases of Investments
(200,257)
—
102,323
(100,000)
Proceeds from Sale of Investments
—
—
—
(3,512)
Payments for Business Acquisitions
(70,328)
(54,765)
(186,642)
(64,830)
Other Investing Activities
(2,397)
1,287
32
110
Cash from Investing Activities
(298,474)
(86,383)
(123,275)
(233,236)
Issuance of Long-Term Debt
—
—
290,094
—
Repayments of Long-Term Debt
—
(69,939)
—
—
Net Issuance / (Repayments) of Long-Term Debt
—
(69,939)
290,094
—
Issuance of Common Shares
3,176
4,294
1,076
3,707
Repurchases of Common Shares
(8,833)
(9,882)
(27,613)
(17,018)
Net Issuance / (Repurchases) of Common Shares
(5,657)
(5,588)
(26,537)
(13,311)
Other Financing Activities
(9,548)
(7,375)
(14,596)
(26)
Cash from Financing Activities
(15,205)
(82,902)
248,961
(13,337)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
4,928
(77)
(11,739)
(5,866)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash